Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 1.48
-3.27 %
$ 6.49 M
Market Cap
-0.64
P/E
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York.[ Read More ]
The intrinsic value of one INBS stock under the base case scenario is HIDDEN Compared to the current market price of 1.48 USD, Intelligent Bio Solutions Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart INBS
FINANCIALS
3.11 M
REVENUE
-10.3 M
OPERATING INCOME
-10.2 M
NET INCOME
-9.57 M
OPERATING CASH FLOW
-221 K
INVESTING CASH FLOW
14.6 M
FINANCING CASH FLOW
872 K
REVENUE
-2.73 M
OPERATING INCOME
-2.69 M
NET INCOME
-2.39 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
42.4 K
FINANCING CASH FLOW
Balance Sheet Decomposition
Intelligent Bio Solutions Inc.
| Current Assets | 8.53 M |
| Cash & Short-Term Investments | 6.3 M |
| Receivables | 978 K |
| Other Current Assets | 1.25 M |
| Non-Current Assets | 5.24 M |
| Long-Term Investments | 0 |
| PP&E | 873 K |
| Other Non-Current Assets | 4.37 M |
| Current Liabilities | 5.45 M |
| Accounts Payable | 602 K |
| Short-Term Debt | 1.06 M |
| Other Current Liabilities | 3.78 M |
| Non-Current Liabilities | 145 K |
| Long-Term Debt | 81.3 K |
| Other Non-Current Liabilities | 63.6 K |
EFFICIENCY
Earnings Waterfall
Intelligent Bio Solutions Inc.
| Revenue | 3.11 M |
| Cost Of Revenue | 1.69 M |
| Gross Profit | 1.43 M |
| Operating Expenses | 11.7 M |
| Operating Income | -10.3 M |
| Other Expenses | -92.2 K |
| Net Income | -10.2 M |
RATIOS
45.81%
GROSS MARGIN
-330.46%
OPERATING MARGIN
-326.40%
NET MARGIN
-121.94%
ROE
-73.71%
ROA
-112.76%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Intelligent Bio Solutions Inc.
| Net Income | -10.2 M |
| Depreciation & Amortization | 1.21 M |
| Capital Expenditures | -221 K |
| Stock-Based Compensation | 230 K |
| Change in Working Capital | -702 K |
| Others | -258 K |
| Free Cash Flow | -9.79 M |
Wall Street Analysts Price Targets
Intelligent Bio Solutions Inc.
INBS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Intelligent Bio Solutions Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Oct 04, 2023
|
Bought 5 K USD
|
TOWERS CHRISTOPHER
Director |
+ 9090
|
0.55 USD |
|
1 year ago
Oct 04, 2023
|
Bought 0 USD
|
TOWERS CHRISTOPHER
Director |
+ 9090
|
0 USD |
|
1 year ago
Oct 04, 2023
|
Bought 0 USD
|
TOWERS CHRISTOPHER
Director |
+ 9090
|
0 USD |
|
1 year ago
Oct 04, 2023
|
Bought 62 K USD
|
Sakiris Spiro Kevin
Chief Financial Officer |
+ 112727
|
0.55 USD |
|
1 year ago
Oct 04, 2023
|
Bought 0 USD
|
Sakiris Spiro Kevin
Chief Financial Officer |
+ 112727
|
0 USD |
|
1 year ago
Oct 04, 2023
|
Bought 0 USD
|
Sakiris Spiro Kevin
Chief Financial Officer |
+ 112727
|
0 USD |
|
1 year ago
Sep 01, 2023
|
Bought 92.5 USD
|
Simeonidis Harry
CEO |
+ 50
|
1.85 USD |
|
1 year ago
Aug 31, 2023
|
Bought 192 USD
|
Simeonidis Harry
CEO |
+ 100
|
1.92 USD |
7. News
Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a strategic partnership with B2i Digital to launch an investor-focused marketing campaign. B2i Digital will employ advanced digital marketing strategies to raise awareness of INBS' patented drug screening technology, which offers a fast, non-invasive, and efficient alternative to traditional drug tests.
globenewswire.com
- 2 weeks ago
Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results
Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary driver Expanded distribution network in Saudi Arabia NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for the fiscal first quarter ended September 30, 2024. The Company expects unaudited revenue of approximately $0.87 million for the three months ended September 30, 2024, representing an increase of 10% year-on-year and 20% quarter-on-quarter.
globenewswire.com
- 2 weeks ago
Intelligent Bio Solutions to Present at the LD Micro Main Event XVII on October 28-30 in Los Angeles
New York, New York--(Newsfile Corp. - October 16, 2024) - Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present in the upcoming LD Micro Main Event XVII on October 28-30, 2024, in Los Angeles. LD Micro Main Event XVII Dates: October 28-30, 2024 Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA Presentation Day and Time: October 30 at 10:00 a.m.
newsfilecorp.com
- 1 month ago
Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek
Transition will Minimize Downtime, Deliver Faster, More Cost-Effective Results, and Improve Overall Safety and Productivity Transition will Minimize Downtime, Deliver Faster, More Cost-Effective Results, and Improve Overall Safety and Productivity
globenewswire.com
- 1 month ago
Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution
NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its distribution partnership with Spirit Group, an Australian, Indigenous-owned marketing and consulting agency, with prominent clients across a wide range of industries, including mining, transportation and construction. Spirit Group will bring INBS' Intelligent Fingerprinting Drug Testing Solution to government and corporate clients across Australia.
globenewswire.com
- 1 month ago
GPS Marine Adopts Intelligent Bio Solutions' Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services
INBS announces the addition of GPS Marine, a leading provider of marine construction and logistics services, to its growing number of customer accounts.
globenewswire.com
- 1 month ago
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of in-clinic testing proposed to the FDA earlier this year in the Company's clinical study plan.
globenewswire.com
- 1 month ago
UK's Largest Greenhouse Complex, Thanet Earth, Adopts Intelligent Bio Solutions' Fingerprint Drug Test to Enhance Workplace Safety
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Thanet Earth, the UK's largest greenhouse complex, has adopted its Intelligent Fingerprinting Drug Screening System for in-house drug testing.
globenewswire.com
- 1 month ago
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights
- Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2024, and provided a business update.
globenewswire.com
- 1 month ago
Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Virtual Conference on September 18-19, 2024
NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a leader in non-invasive drug testing technology, today announced that its management team will participate in the Sidoti Small-Cap Virtual Conference being held on September 18-19, 2024.
globenewswire.com
- 2 months ago
Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its progress toward completion of the clinical study plan required for its FDA 510(k) submission.
globenewswire.com
- 2 months ago
Intelligent Bio Solutions Inc. Reports 118% Year-Over-Year Growth in Customer Employee Base, Reaching an Estimated Total of 1.4 Million Employees
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a leader in non-invasive drug testing technology, today announced significant growth in its customer employee base, reporting a 118% fiscal year-over-year increase in the estimated total number of employees across its customer base.
globenewswire.com
- 2 months ago
8. Profile Summary
Intelligent Bio Solutions Inc. INBS
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 6.49 M
Dividend Yield
0.00%
Description
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Contact
142 West 57th Street, New York, NY, 10019
https://gbs.inc
IPO Date
Dec. 23, 2020
Employees
50
Officers
Mr. Harry Simeonidis
President & Chief Executive Officer
Mr. Alex Arzeno
Vice President of Investor Relations
Mr. Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law
Chief Financial Officer